<DOC>
	<DOCNO>NCT01087515</DOCNO>
	<brief_summary>The aim study investigate immunomodulatory potential Isolated Plasmacytoide Dendritic Cells ( pDCs ) Regulatory T-cells ( TREGs ) isolate clinical grade magnetic bead isolation technique ( MACS® ) antigen present cell-induced proliferation lymphocytes allergen uptake vitro cell culture system .</brief_summary>
	<brief_title>Pilot Study Cell Based Therapies Patients With Asthma</brief_title>
	<detailed_description>pDCs well TREGs co-incubated generate allergen present cell , lymphocyte , allergen . For vitro experimentation immune cell collect blood grass mix house dust mite sensitize atopic/asthmatic patient .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male subject suffer allergic rhinitis and/or allergic asthma timothy grass pollen ( phleum pratense ) and/or house dust mite . age 1860 year , Nonsmokers smoker history le 1 pack year smoke within last 12 month . Positive skin prick test timothy grass pollen ( phleum pratense ) and/or house dust mile within 12 month Able willing give write informed consent Hemoglobin ≥135 g/l Hematocrit ≥ 0,40 Body weight ≥ 50 kg Body Mass Index ( BMI ) within range 1932 kg/m² History low respiratory tract infection /or exacerbation asthma within four week prior inform consent visit Febrile illness within four week trial examination Administration oral , injectable , dermal corticosteroid within last 8 week intranasal and/or inhaled corticosteroid within last 4 week . Intake methylxanthines , antihistamine , antileukotrienes , oral cromolyn sodium , oral nedocromil sodium Past present disease , judge investigator , may affect outcome trial . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , endocrine disease , pulmonary disease ( include confine chronic bronchitis , emphysema , tuberculosis , bronchiectasis cystic fibrosis ) . Specific immunotherapy ( SIT ) within last two year prior screen Participation another clinical trial 30 day prior enrollment Donation 500 ml blood precede 9 week trialexamination Hemoglobin normal low limit History drug and/or alcohol abuse dependence within 12 month trial Risk noncompliance trial procedure Suspected inability understand protocol requirement , instruction trialrelated restriction , nature , scope , possible consequence trial Patient test human immunodeficiency virus ( HIV ) 1/2Ab , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) positive</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>